Blog: Affordable Care Act
April 1, 2015 | Affordable Care Act, USA
What does the future hold for the US pharma industry?
Everywhere you go in the States, you hear talk of the Affordable Care Act, also known as ObamaCare. In essence, the ACA is designed to broaden coverage to the millions of Americans who have not had healthcare in the past due to not being employed or just not being able to afford it. ACA had a rocky time getting passed into law and now that it has launched on January 1, 2014, things are not getting much easier. After the President promised that no one who likes his/her doctor would have to switch doctors, some folks are being dropped by their insurance and do have to leave their doctors. Younger people almost certainly have to pay more than they have been paying for coverage because the way the new system is structured, younger, healthier people are underwriting the costs for older people who utilize the healthcare system more frequently (and at greater cost). At the core of the debate is a values questions: some people truly believe that everyone should have access to the healthcare system as provided by the ACA. Others exude a really American spirit of not wanting any government intervention or interference in their lives. So despite the fact that this program might be advantageous to many, it represents an intrusion. This disagreement is unlikely to be easily resolved as it is a core values question.
It has been almost a given that full time employees offer some level of healthcare coverage to employees and some employers are taking advantage of this shift in the landscape to divorce employment from healthcare benefits and force their employees to shop independently for coverage on the newly created exchanges. In fact, this has happened to my own husband. So this represents added expense to the employees, unless the employers decide to underwrite the cost in some way (which has yet to be determined). This is “a great unknown” and something that will be determined company to company, not on a national level.
There are some facts that are emerging, although the system is still unfolding. Some folks will have to change physicians and physicians will have to see more patients, possibly at a lower reimbursement rate than before. The rates themselves are still unclear and may not be clear for quite some time. The system is structured so that everyone will have access to care; in fact, everyone must have access to care. That means that there are financial penalties if people don’t sign up.
So everyone is a bit at sea. Pharma companies, too are wondering about the impact of the ACA on their worlds. What guidelines will physicians have to follow in prescribing? What tests will be covered? What types of reporting will they have do (electronic record keeping)? I spoke to my colleague from our sister company, Access Partnership about this. His idea is that things are unclear in part because, although the Supreme Court upheld the centerpiece of the Affordable Care Act more than a year ago, there are still several legal challenges to the new system, which may slow down the implementation and make it difficult to envision how the new system will play out over time.
As of right now, the Affordable Care Act is just beginning and it is difficult to see “around the next bend” as to what the long term implications will be for the interested parties (and by that I mean everyone!).
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1Pj6vu1
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...
How we elevated HCP market research engagement and insights using AI avatars for an immersive experience
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...
How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...
The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI
Authored by Paul Reed and Anabelle Gall
Latest European developments and new talent at Research Partnership
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...
New syndicated report – Living with Ulcerative Colitis 2024
Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...
Webcast: AI in MRX: Harnessing the power of AI + people
Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...
Navigating challenges of MedTech research with rare-disease patients
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.